ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
69.09
-1.82 (-2.57%)
At close: Aug 6, 2025, 4:00 PM
69.55
+0.46 (0.67%)
After-hours: Aug 6, 2025, 7:39 PM EDT
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Achilles Therapeutics stock have a consensus rating of "Buy" and an average price target of $74.86, which forecasts a 8.35% increase in the stock price over the next year. The lowest target is $12 and the highest is $112.
Price Target: $74.86 (+8.35%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Achilles Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 2 | 2 | 2 | 5 | 5 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 5 | 5 | 5 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $70 → $112 | Buy | Maintains | $70 → $112 | +62.11% | Jul 29, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $70 | Buy | Maintains | $42 → $70 | +1.32% | Jul 23, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $45 → $101 | Buy | Maintains | $45 → $101 | +46.19% | Jul 23, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $50 → $101 | Strong Buy | Maintains | $50 → $101 | +46.19% | Jul 23, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $33 → $95 | Buy | Maintains | $33 → $95 | +37.50% | Jul 23, 2025 |
Financial Forecast
Revenue This Year
4.42M
from 10.79M
Decreased by -59.04%
Revenue Next Year
6.25M
from 4.42M
Increased by 41.36%
EPS This Year
-2.78
from -2.80
EPS Next Year
-1.17
from -2.78
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.7M | 14.2M | 176.4M | ||
| Avg | 4.4M | 6.2M | 134.9M | ||
| Low | n/a | n/a | 94.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.5% | 220.7% | 2,723.3% | ||
| Avg | -59.0% | 41.4% | 2,059.1% | ||
| Low | - | - | 1,413.6% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -1.49 | 4.95 |
| Avg | -2.78 | -1.17 |
| Low | -3.08 | -4.04 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.